70 The latest research highlights a significant advancement in managing desmoid tumours, a rare and locally aggressive condition affecting soft tissues. Percutaneous cryoablation, a minimally invasive treatment, has emerged as a cost-effective alternative to conventional surgery, particularly within Spain’s healthcare system. The findings were published in the journal Insights into Imaging. Desmoid tumours, though benign, can cause substantial complications such as pain, disability, and recurrence after treatment. Historically, surgery has been the standard intervention, offering local tumour control but presenting challenges like high recurrence rates, extended recovery periods, and increased healthcare costs. The advent of percutaneous cryoablation marks a pivotal shift towards a more efficient and less invasive treatment method. The procedure involves freezing the affected tissue, effectively halting tumour growth while minimising damage to surrounding structures. It requires shorter hospital stays and has a lower complication rate than conventional surgery. According to the study, the total cost per patient for cryoablation is €5,774.78 annually, significantly lower than the €6,780.98 incurred by surgical interventions. For Spain’s 80 eligible patients, this translates into potential yearly savings of approximately €80,000. One of the study’s strengths lies in its comprehensive economic analysis, validated by clinical experts. The research incorporated hospital-specific data and patient demographics, ensuring a robust cost comparison. Sensitivity analyses further confirmed the stability of the cost advantage even when key variables were adjusted. While cryoablation offers clear economic benefits, its clinical efficacy is equally noteworthy. The technique achieves comparable long-term tumour control to surgery, with the added advantage of reduced recovery times and fewer complications. This positions it as a viable option not only for primary treatment but also for cases of recurrent tumours. Despite its promise, the study acknowledges limitations. The reliance on data from a few hospitals may not reflect national trends. Additionally, the lack of a national registry for desmoid tumour cases means broader generalisation is challenging. Further research could address these gaps and explore cryoablation’s applicability to other tumour types. As healthcare systems globally grapple with rising costs, innovations like percutaneous cryoablation underscore the importance of combining clinical efficacy with economic sustainability. This research sets the stage for adopting less invasive therapies, providing patients with improved outcomes and alleviating the financial burden on healthcare providers.